The biology of JC virus and progressive multifocal leukoencephalopathy David B. CliffordEugene O. Major Guest Editorial Pages: 279 - 279
A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region Peter N. JensenEugene O. Major Basic Science and Immunobiology Report Pages: 280 - 287
Physical and functional interaction between viral and cellular proteins modulate JCV gene transcription Mahmut SafakKamel Khalili Basic Science and Immunobiology Report Pages: 288 - 292
Structure and function of JC virus T′ proteins Richard J. Frisque Basic Science and Immunobiology Report Pages: 293 - 297
Analysis of minimal sequences on JC virus VP1 required for capsid assembly Wei-Chih OuLing-Hua ChenDeching Chang Basic Science and Immunobiology Report Pages: 298 - 301
Distribution and function of JCV agnoprotein Yuki OkadaShuichi EndoKazuo Nagashima Basic Science and Immunobiology Report Pages: 302 - 306
A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: Implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy Walter J. Atwood Basic Science and Immunobiology Report Pages: 307 - 310
Immune response in progressive multifocal leukoencephalopathy: An overview Thomas WeberF. WeberW. Lüke Immunovirology Report Pages: 311 - 317
JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy Renaud A. Du PasquierKatherine W. ClarkIgor J. Koralnik Immunovirology Report Pages: 318 - 322
Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era Andrea AntinoriAdriana AmmassariAndrea De Luca Epidemiology Report Pages: 323 - 328
Epidemiological evidence and molecular basis of interactions between HIV and JC virus Joseph R. BergerAshok ChauhanAvi Nath Epidemiology Report Pages: 329 - 338
Predicted amino acid sequences for 100 JCV strains Christopher L. CubittXiaohong CuiGerald L. Stoner Epidemiology Report Pages: 339 - 344
Excretion and transmission of JCV in human populations Sílvia Bofill-MasRosina Girones Epidemiology Report Pages: 345 - 349
Challenges for clinical trials on progressive multifocal leukoencephalopathy David B. Clifford Clinical Trial Report Pages: 350 - 352
The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS M. D. GeschwindR. I. SkolaskyJ. C. McArthur Clinical Trial Report Pages: 353 - 357
The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy Paola CinqueChiara PierottiAdriano Lazzarin Clinical Trial Report Pages: 358 - 363
Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study Andrea De LucaMaria Letizia GiancolaAndrea Antinori Clinical Trial Report Pages: 364 - 368
Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy Constantin T. YiannoutsosAndrea De Luca Clinical Trial Report Pages: 369 - 374
Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: A monocenter observational study with clinical and JC virus load monitoring Jacques GasnaultPascale KousignianYassine Taoufik Clinical Trial Report Pages: 375 - 381
Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML) Robert M. LevyEugene MajorDennis Groothius Clinical Trial Report Pages: 382 - 385
Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside A. J. Aksamit Clinical Trial Report Pages: 386 - 390
